BWA
GPCR icon

Basecamp Wealth Advisors’s Structure Therapeutics GPCR Stock Holding History

Basecamp Wealth Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-84
Closed -$4.05K – 1894
2026
Q1 		$4.05K Buy
+84
New +$5.75K ﹤0.01% 1230

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Basecamp Wealth Advisors's GPCR Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 84 shares — an estimated $4.05K sold.

Basecamp Wealth Advisors first reported a position in GPCR in Q1 2026 and held it in 1 quarter. The position peaked at $4.05K in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Basecamp Wealth Advisors reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 84 Structure Therapeutics shares in Q2 2026, an estimated $4.05K.
  • Basecamp Wealth Advisors first reported a position in Structure Therapeutics in Q1 2026 and held it in 1 quarter.
  • Basecamp Wealth Advisors's Structure Therapeutics position peaked at $4.05K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.